Neuroblastoma remains a serious childhood malignancy, accounting for 8-10% of all childhood cancers. Prognosis for patients with advanced disease remains poor, with a 2-year disease-free survival of only 10-30%. Recent clinical research has shown that for patients with advanced disease, bone marrow transplantation (BMT) with purged autologous marrow improves event-free survival. However, the majority of patients still relapse within 2 years after transplant. Immune intervention early after transplant might improve survival of these patients. Our preliminary data in an experimental model indicates that T cells capable of responding to a neuroblastoma tumor vaccine are required for induction of anti-tumor immunity after BMT. Immune regulatory T cells (CD4+CD25+) have been found to play a key role in regulating self-non-self recognition by the immune system, and it appears that these cells can be recruited or induced by tumors to prevent immune activation and tumor elimination. The presence of these regulatory cells in the diseased host may in part explain the low degree of success with tumor vaccines. The time period early after BMT, before regulatory T cells have reestablished dominant peripheral tolerance, offers a unique setting to induce effective anti-tumor immunity by combining T cell add-back and tumor vaccination with the inhibition of CD4+25+ T cell-mediated tolerance. Utilizing a mouse model for neuroblastoma, Neuro-2a, we hypothesize that: (1) Using a novel technology, nucleofection, neuroblastoma can be genetically engineered with DNA plasmid vectors to rapidly and efficiently express costimulatory/accessory molecules (CDS0, CD86, ICAM-1, and/or 4-1BBL), and that these engineered cells can serve as a potent tumor vaccine; (2) CD25+ cells suppress anti-neuroblastoma immunity, and depletion of these regulatory T cells augments immunity during tumor vaccination by increasing the contribution of multiple immune effector populations; and (3) Optimal T cell immunity to neuroblastoma can be induced early post-BMT by combining T cell addback with novel tumor vaccines in a setting where cellular mediators of tolerance induction (to tumor) have been removed. The goal of these studies is to provide preclinical data that will lead to the testing of novel immunotherapeutic strategies to prevent neuroblastoma relapse after BMT. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA100030-03
Application #
7057879
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Yovandich, Jason L
Project Start
2004-06-15
Project End
2009-04-30
Budget Start
2006-06-01
Budget End
2007-04-30
Support Year
3
Fiscal Year
2006
Total Cost
$300,274
Indirect Cost
Name
Medical College of Wisconsin
Department
Pediatrics
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Barr, Kristen M; Jing, Weiqing; Hallett, William H D et al. (2013) Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity. J Immunother 36:41-51
Jing, Weiqing; Yan, Xiaocai; Hallett, William H D et al. (2011) Depletion of CD25? T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. Blood 117:6952-62
Kohler, M Eric; Hallett, William H D; Chen, Qing-Rong et al. (2010) Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. Cell Immunol 265:65-73
Kohler, M Eric; Johnson, Bryon D; Palen, Katie et al. (2010) Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data. Cancer Sci 101:2316-24
Jing, Weiqing; Gershan, Jill A; Johnson, Bryon D (2009) Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood 113:4449-57
Yan, Xiaocai; Johnson, Bryon D; Orentas, Rimas J (2008) Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. J Immunol 181:4621-31
Zhou, Qiang; Yan, Xiaocai; Gershan, Jill et al. (2008) Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. J Immunol 181:1877-86
Jing, Weiqing; Orentas, Rimas J; Johnson, Bryon D (2007) Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biol Blood Marrow Transplant 13:277-92
Zhou, Qiang; Johnson, Bryon D; Orentas, Rimas J (2007) Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. Cell Immunol 245:91-102
Johnson, Bryon D; Jing, Weiqing; Orentas, Rimas J (2007) CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother 30:203-14

Showing the most recent 10 out of 12 publications